News and Updates
iVeena Announces Notice of Allowance for US Patent Application Covering IVMED-80 for Treatment of Keratoconus
April 27, 2021 – Salt Lake City, UT – iVeena, a clinical stage ophthalmology company addressing unmet medical need in the pharmacologic treatment of corneal dystrophies and myopic conditions, announce...
iVeena announces the appointment of Paul Karpecki, OD, FAAO to the iVeena Scientific Advisory Board.
Dr. Karpecki is an internationally recognized opinion leader in the optometry field. Dr. Karpecki received his doctor of optometry degree from Indiana University and completed a fellowship in Medi...
$1.68 million in Grants Given For Keratoconus Orphan Drug Candidate
Dr. Sarah Molokhia, PI for a SBIR Phase 2 grant and Adjunct Assistant Professor at Department of Pharmaceutics and Pharmaceutical Chemistry at the University of Utah and iVeena is pleased to announce...
iVeena Announces Positive Topline Results; IVMED-80 Advancing to Phase 3 Clinical Trials
SALT LAKE CITY--(BUSINESS WIRE)--iVeena is pleased to announce the topline results of its recently completed Phase 1/2a clinical trial, “A Randomized, Double-Masked, Trial of IVMED-80 Eyedrops for Tre...
MillenialEYE Interviews iVeena Founder Dr. Bala Ambati
https://millennialeye.com/articles/july-aug-20/the-innovators-experience/?single=true
Page 2 of 9